J Cardiovasc Ultrasound.  2016 Jun;24(2):104-105. 10.4250/jcu.2016.24.2.104.

Neutrophil-to-Lymphocyte Ratio for Risk Assessment in Coronary Artery Disease and Carotid Artery Atherosclerosis

• Park JB

• KMID: 2308695
• DOI: http://doi.org/10.4250/jcu.2016.24.2.104

Abstract

No abstract available.

MeSH Terms

Atherosclerosis*
Carotid Arteries*
Coronary Artery Disease*
Coronary Vessels*
Risk Assessment*

Reference

1. Wong ND. Epidemiological studies of CHD and the evolution of preventive cardiology. Nat Rev Cardiol. 2014; 11:276–289.

2. Committee on Preventing the Global Epidemic of Cardiovascular Disease: Meeting the Challenges in Developing Countries, Board on Global Health, Institute of Medicine. Promoting cardiovascular health in the developing world: a critical challenge to achieve global health. Washington, DC: National Academies Press;2010.

3. Libby P. Inflammation in atherosclerosis. Nature. 2002; 420:868–874.

4. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005; 352:1685–1695.

5. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, Lowe GD, Pepys MB, Gudnason V. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004; 350:1387–1397.

6. Engström G, Hedblad B, Stavenow L, Tydén P, Lind P, Janzon L, Lindgärde F. Fatality of future coronary events is related to inflammationsensitive plasma proteins: a population-based prospective cohort study. Circulation. 2004; 110:27–31.

7. Kim BJ, Cho SH, Cho KI, Kim HS, Heo JH, Cha TJ. The combined impact of neutrophil-to-lymphocyte ratio and type 2 diabetic mellitus on significant coronary artery disease and carotid artery atherosclerosis. J Cardiovasc Ultrasound. 2016; 24:115–122.

8. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002; 347:1557–1565.

9. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation. 2003; 107:363–369.

10. Morrow DA, Rifai N, Antman EM, Weiner DL, McCabe CH, Cannon CP, Braunwald E. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol. 1998; 31:1460–1465.

11. Mueller C, Buettner HJ, Hodgson JM, Marsch S, Perruchoud AP, Roskamm H, Neumann FJ. Inflammation and long-term mortality after non-ST elevation acute coronary syndrome treated with a very early invasive strategy in 1042 consecutive patients. Circulation. 2002; 105:1412–1415.

12. Bhatt DL, Topol EJ. Need to test the arterial inflammation hypothesis. Circulation. 2002; 106:136–140.

13. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation. 2003; 107:391–397.

14. Pradhan AD, Manson JE, Rossouw JE, Siscovick DS, Mouton CP, Rifai N, Wallace RB, Jackson RD, Pettinger MB, Ridker PM. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative observational study. JAMA. 2002; 288:980–987.

15. C Reactive Protein Coronary Heart Disease Genetics Collaboration (CCGC). Wensley F, Gao P, Burgess S, Kaptoge S, Di Angelantonio E, Shah T, Engert JC, Clarke R, Davey-Smith G, Nordestgaard BG, Saleheen D, Samani NJ, Sandhu M, Anand S, Pepys MB, Smeeth L, Whittaker J, Casas JP, Thompson SG, Hingorani AD, Danesh J. Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data. BMJ. 2011; 342:d548.

16. Brunner EJ, Kivimäki M, Witte DR, Lawlor DA, Davey Smith G, Cooper JA, Miller M, Lowe GD, Rumley A, Casas JP, Shah T, Humphries SE, Hingorani AD, Marmot MG, Timpson NJ, Kumari M. Inflammation, insulin resistance, and diabetes--Mendelian randomization using CRP haplotypes points upstream. PLoS Med. 2008; 5:e155.